This is in marked contrast to the use of histamine H2-receptor antagonists, which are also effective in ZES patients, but which usually require high, frequent (every 4–6 h) dosing to be effective [28,52,53,187,287] (Table 1). Here, HRH2 is linked to Zollinger-Ellison syndrome.